Department of Oral and Maxillofacial Surgery, Istanbul University, Faculty of Dentistry, Millet Cd, 34093 Fatih, Istanbul, Turkey.
Department of Oral and Maxillofacial Surgery, Karabuk University, Faculty of Dentistry, Demir Çelik Kampüsü 78050 Karabuk, Turkey.
Niger J Clin Pract. 2022 May;25(5):641-646. doi: 10.4103/njcp.njcp_1623_21.
This study aimed to evaluate acute postoperative pain management and trismus in 35 patients undergoing extractions of the two mandibular third molars, in mesioangular positions, at two different visits who consumed nimesulide + thiocolchicoside or only nimesulide.
According to the medication given, the patients were divided into two groups. Following the first surgery of the impacted third molar patients were given nimesulide (100 mg) + thiocolchicoside (8 mg) together. The healing period was waited for 15 days and in the poursuite of the second surgery, only nimesulide (100 mg) was administered every 12 hours for 7 days. Visual analog scales (VAS) were used to assess the pain in the 6, 8, 12, 24, and 48 hours and on the 3, 5, and 7 days postoperatively. Digital calipers were used to measure (in mm) the mouth opening capacity pre and postoperatively on the 2 and 7 days, respectively.
Regarding pain alleviation, the nimesulide + thiocolchicoside group was more effective than the nimesulide group. The VAS levels of nimesulide + thiocolchicoside at the 6, 8, 12, 24, and 48 hours and on the 3 and 5 days were significantly lower than the nimesulide group. The mouth opening was observed higher in the nimesulide + thiocolchicoside group than in the nimesulide group (P > 0.05). In the nimesulide group, at the end of the 7 day, the trismus measurements were less than the preoperative measurements. There was no statistically significant difference in the Nimesulide + Thiocolchicoside group in the preop-7 days.
Nimesulide (100 mg) + thiocolchicoside (8 mg) combination has higher analgesic efficacy and better trismus outcomes compared to only nimesulide (100 mg) when orally administered following mandibular third molar surgeries.
本研究旨在评估 35 例接受下颌第三磨牙(近中颊向位)拔除术的患者在两次就诊时分别接受尼美舒利+硫代秋水仙碱和仅接受尼美舒利治疗后的急性术后疼痛管理和牙关紧闭情况。
根据所给予的药物,将患者分为两组。在进行第一次手术(拔除第三磨牙)后,患者同时给予尼美舒利(100mg)+硫代秋水仙碱(8mg)。等待愈合期为 15 天,在第二次手术中,仅给予尼美舒利(100mg),每 12 小时口服一次,共 7 天。使用视觉模拟评分(VAS)评估术后 6、8、12、24 和 48 小时以及术后第 3、5 和 7 天的疼痛。使用数字卡尺分别在术后第 2 和 7 天测量(mm)术前和术后的张口度。
在缓解疼痛方面,尼美舒利+硫代秋水仙碱组比尼美舒利组更有效。尼美舒利+硫代秋水仙碱组在术后 6、8、12、24 和 48 小时以及术后第 3 和 5 天的 VAS 评分明显低于尼美舒利组。尼美舒利+硫代秋水仙碱组的张口度明显高于尼美舒利组(P>0.05)。在尼美舒利组,第 7 天结束时,测量的张口度小于术前测量值。尼美舒利+硫代秋水仙碱组在术前与第 7 天之间没有统计学上的显著差异。
与仅给予尼美舒利(100mg)相比,下颌第三磨牙拔除术后口服尼美舒利(100mg)+硫代秋水仙碱(8mg)联合治疗具有更高的镇痛效果和更好的牙关紧闭结果。